Overview

• Studies at ASCO show that tailoring immunotherapy timing and dosing to patients’ daily routines can enhance efficacy and reduce adverse effects.
• Trials indicate that administering immunotherapy earlier in treatment regimens improves patient outcomes with approved drugs now accessible in clinical practice.
• Timothée Olivier cautioned that trial results may not reflect outcomes in real-world patients, especially those who are older or have comorbidities.
• A phase 1 personalized therapeutic vaccine against head and neck cancers presented by Institut Curie researchers produced encouraging preliminary tumor responses.
• Continued immunotherapy innovations over the past decade and a half have markedly boosted cancer patient survival, driving further research into personalized approaches.